Currently, there are 12 ongoing clinical trials evaluating the CB-839 in patients with colorectal cancer (NCT02861300 and NCT03263429), myelodysplastic syndrome (NCT03047993), advanced stage non-small cell lung cancer (NCT04250545 and NCT03831932), diffuse astrocytoma (NCT03528642), ovarian cancer (NCT03944902), refractory multiple myeloma (NCT03798678), advanced or metastatic solid tumors (NCT03965845), metastatic renal cell carcinoma (NCT03428217), malignancies with NF1, KEAP1/NRF2, or STK11/LKB1 mutations (NCT03872427), and non-squamous non-small-cell lung cancer (NCT04265534). Here, STK11 is linked to plasma cell myeloma.